SEC Comment Letter for MetaVia Inc. (MTVA) (CIK 0001638287) (MTVA) — Aug 28, 2018

MetaVia Inc. (MTVA) (CIK 0001638287)
Date: Aug. 28, 2018 · CIK: 0001638287 · Accession: 0000000000-18-026654

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37809

Date

August 27, 2018

Author

Jeffrey S. Mathiesen

Form

UPLOAD

Company

MetaVia Inc. (MTVA) (CIK 0001638287)

Letter

August 27, 2018 Jeffrey S. Mathiesen Chief Financial Officer Gemphire Therapeutics Inc. 17199 N. Laurel Park Dr. Suite 401 Lavonia, MI 48152 Re:Gemphire Therapeutics Inc. Form 10-K for the Fiscal year Ended December 31, 2017 Filed March 20, 2018 File No. 001-37809 Dear Mr. Mathiesen: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

August 27, 2018
Jeffrey S. Mathiesen
Chief Financial Officer
Gemphire Therapeutics Inc.
17199 N. Laurel Park Dr.
Suite 401
Lavonia, MI 48152
Re:Gemphire Therapeutics Inc.
Form 10-K for the Fiscal year Ended December 31, 2017
Filed March 20, 2018
File No. 001-37809
Dear Mr. Mathiesen:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io